Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Denium Therapeutics, Inc - Common Shares (MNMD)
Company Research
Source: Yahoo! Finance
See our latest analysis for Mind Medicine (MindMed). That momentum has been building as investors reassess the risk reward trade off in psychedelic therapeutics. The stock has seen a 30 day share price return of 14.73% and a standout three year total shareholder return of 395.65% from today's $12.54 share price. If MindMed has caught your eye, it can be useful to compare it with other niche players in healthcare and biotech by exploring healthcare stocks With Phase 3 and Phase 1 programs advancing, a track record of strong multi year returns, and analysts targeting more than double the current price, is MindMed still a misunderstood value, or has the market already priced in the next leg of growth? On a price to book basis, MindMed looks expensive at 9.5x book value compared to both its US pharmaceuticals peers and the broader industry, despite the recent share price strength. The price to book ratio compares the company's market value with the net assets on its balance she
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Denium Therapeutics, Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Assessing Mind Medicine (MNMD) Valuation After A Strong Year Of Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.MarketBeat
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]Seeking Alpha
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 1/12/26 - Form 8-K
- 12/29/25 - Form 4
- 12/29/25 - Form 4
- MNMD's page on the SEC website